SCHEMBL13638616

SCHEMBL13638616

Bc1ccc(S(=O)(=O)Nc2cccc3cccnc23)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 9/20 0.76
GLO1 Q04760 8/20 0.76
TDP1 Q9NUW8 7/20 0.76
AGTR1 P30556 2/20 0.76
NFKBIA P25963 2/20 0.76
G6PD P11413 1/20 0.76
METAP2 P50579 1/20 0.76
METAP1 P53582 1/20 0.76
PAX8 Q06710 1/20 0.76
ATM Q13315 1/20 0.76
KMT2A Q03164 4/20 0.75
MEN1 O00255 3/20 0.75
ALDH1A1 P00352 2/20 0.75
OPRK1 P41145 2/20 0.75
HTT P42858 2/20 0.75
NPSR1 Q6W5P4 2/20 0.75
MITF O75030 1/20 0.75
S1PR4 O95977 1/20 0.75
LMNA P02545 1/20 0.75
MAPT P10636 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL442367 0.87 SLC40A1 (1.00) SLC40A1GLO1TDP1AGTR1NFKBIA
SCHEMBL29799662 0.86 TDP1 (1.00) SLC40A1GLO1TDP1AGTR1NFKBIA
SCHEMBL6981081 0.86 SLC40A1 (1.00) SLC40A1GLO1TDP1AGTR1NFKBIA
SCHEMBL4471796 0.86 TDP1 (1.00) SLC40A1GLO1TDP1AGTR1NFKBIA
SCHEMBL6978005 0.86 GLO1 (1.00) SLC40A1GLO1TDP1AGTR1NFKBIA
SCHEMBL30925586 0.86 SLC40A1 (1.00) SLC40A1GLO1TDP1AGTR1NFKBIA
SCHEMBL3825367 0.86 TDP1 (1.00) SLC40A1GLO1TDP1AGTR1NFKBIA
SCHEMBL13485950 0.86 SLC40A1 (0.80) SLC40A1GLO1TDP1AGTR1NFKBIA
SCHEMBL27916992 0.86 TDP1 (1.00) SLC40A1GLO1TDP1AGTR1NFKBIA
SCHEMBL7746129 0.85 SLC40A1 (0.97) SLC40A1GLO1TDP1AGTR1NFKBIA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A SLC40A1 4638/4885GLO1 865/4885TDP1 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.